Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | CASP9 | P55211 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.54 |
| ▸ | MMP14 | P50281 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.52 |
| ▸ | CTSS | P25774 | 4/20 | 0.52 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764419 | 0.90 | MMP9 (0.65) | MMP9CASP1CASP3CASP7CASP9 | |
| SCHEMBL7764455 | 0.90 | MMP9 (0.65) | MMP9CASP1CASP3CASP7CASP9 | |
| SCHEMBL25908024 | 0.87 | MMP9 (0.53) | MMP9CTSKMMP14CYP3A4TSHR | |
| SCHEMBL10797754 | 0.86 | CTSL (0.66) | MMP9CTSKMMP14CTSLCTSS | |
| SCHEMBL19015747 | 0.86 | MMP9 (0.62) | MMP9CASP1CTSKMMP14CYP3A4 | |
| SCHEMBL9697579 | 0.85 | MME (0.65) | CASP1CASP3CASP7CASP9CTSL | |
| SCHEMBL30902878 | 0.85 | MME (0.56) | CASP1CASP3CASP7CASP9CTSK | |
| SCHEMBL13589982 | 0.84 | CTSK (0.64) | CTSKCTSLCTSSCTSBMME | |
| SCHEMBL14433713 | 0.84 | CTSK (0.64) | CTSKCTSLCTSSCTSBMME | |
| SCHEMBL30460502 | 0.83 | ATM (0.68) | MMP9CTSKCYP3A4TSHRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | CELGENE CORPORATION | 2023-07-27 | — | — | US | disclosed |
| EP-0688760-B1 | Addition salts of acyl-amino acids and alpha-aryl-amines and process for the optical resolution of alpha-arylamines | AJINOMOTO KK (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0845455-A1 | Addition salts of acyl-amino acids and alpha-arylamines and process for the optical resolution of alpha-arylamines | Ajinomoto Co., Inc. (JP) | 1998-06-03 | — | — | EP | disclosed |
| EP-0688760-A1 | Addition salts of acyl-amino acids and alpha-aryl-amines and process for the optical resolution of alpha-arylamines | Ajinomoto Co., Inc. (JP) | 1995-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234914-A1 | PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE | UMPS, DHPS, NT5C3B | MMP9 3902/4885CASP1 3032/4885CASP3 2399/4885 |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | UMPS, DHPS, NT5C3B | MMP9 3902/4885CASP1 3032/4885CASP3 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.